8-Amino-Adenosine Inhibits Multiple Mechanisms of Transcription
Authors:
Open Access
- 1 January 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 9 (1) , 236-245
Abstract
Roscovitine and flavopiridol suppress cyclin-dependent kinase 7 (CDK7) and CDK9 activity resulting in transcription inhibition, thus providing an alternative mechanism to traditional genotoxic chemotherapy. These agents have been effective in slow or nonreplicative cell types. 8-Amino-adenosine is a transcription inhibitor that has proved very effective in multiple myeloma cell lines and primary indolent leukemia cells. The objective of the current work was to define mechanisms of action that lead to transcription inhibition by 8-amino-adenosine. 8-Amino-adenosine is metabolized into the active triphosphate (8-amino-ATP) in cells. This accumulation resulted in a simultaneous decrease of intracellular ATP and RNA synthesis. When the effects of established ATP synthesis inhibitors and transcription inhibitors on intracellular ATP concentrations and RNA synthesis were studied, there was a strong correlation between ATP decline and RNA synthesis. This correlation substantiated the hypothesis that the loss of ATP in 8-amino-adenosine–treated cells contributes to the decrease in transcription due to the lack of substrate needed for mRNA body and polyadenylation tail synthesis. RNA polymerase II COOH terminal domain phosphorylation declined sharply in 8-amino-adenosine–treated cells, which may have been due to the lack of an ATP phosphate donor or competitive inhibition with 8-amino-ATP at CDK7 and CDK9. Furthermore, 8-amino-ATP was incorporated into nascent RNA in a dose-dependent manner at the 3′-end resulting in transcription termination. Finally, in vitro transcription assays showed that 8-amino-ATP competes with ATP for incorporation into mRNA. Collectively, we have concluded that 8-amino-adenosine elicits effects on multiple mechanisms of transcription, providing a new class of transcription inhibitors. Mol Cancer Ther; 9(1); 236–45Keywords
This publication has 50 references indexed in Scilit:
- Preclinical activity of 8‐chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesisBritish Journal of Haematology, 2009
- Inhibition of ATP synthase by chlorinated adenosine analogueBiochemical Pharmacology, 2009
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemiaBlood, 2009
- The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationThe EMBO Journal, 2008
- Targeting MET transcription as a therapeutic strategy in multiple myelomaCancer Chemotherapy and Pharmacology, 2008
- Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cellsBlood, 2006
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Phosphorylation of RNA polymerase II C-terminal domain and transcriptional elongationNature, 1994
- 5,6-Dichloro-1-β-D-Ribofuranosylbenzimidazole Inhibits Initiation of Nuclear Heterogeneous RNA Chains in HeLa CellsScience, 1976
- The influence of 2-deoxy-d-glucose on the nucleotide content of ehrlich ascites carcinoma cellsBiochimica et Biophysica Acta (BBA) - Specialized Section on Nucleic Acids and Related Subjects, 1964